While the scale of the currency headwinds in Roche’s first-quarter financial update caught many off guard, the company’s ...

New York, April 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global SERD Therapeutics Market: Focus on Product, Therapy, Country Data (14 Countries), and ...

DelveInsight’s SERD Market Insights report includes a comprehensive understanding of current prescribing patterns and in patients with or without emerging oral SERDs in both early and advanced forms ...

Sanofi’s oral selective estrogen receptor degrader (SERD) amcenestrant has flunked a pivotal trial. The failure of amcenestrant as a second-line or later treatment of ER+/HER2- advanced or metastatic ...

Just days ago, Sanofi sent its oral selective estrogen receptor degrader (SERD) for breast cancer to the trash can. But over in Italy, a biotech is plodding forward with its own candidate, with the EU ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging oral ...

At the San Antonio Breast Cancer Symposium (SABCS), researchers presented findings from two phase III trials -- EMERALD and PADA-1-- that may help oncologists identify which metastatic breast cancer ...

Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from ...

Earlier this month, InnovationAus published an excellent article by Dr John H. Howard entitled, SERD's unanswered questions on business incentives. The article looked at three areas of concern ...

Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market ...